Lotte Bio launches ADC services; Ypsomed to focus on self-injection business
Title
Lotte Biologics Launches Full-Scale ADC Services; Ypsomed Refocuses on Self-Injection Business
Keywords
- Lotte Biologics
- Antibody-Drug Conjugate (ADC)
- Contract Development and Manufacturing Organization (CDMO)
- ADC manufacturing facility
- Syracuse Bio Campus
- Biotech partnerships
- Ypsomed
- Self-injection devices
- Biopharmaceutical manufacturing
Key Facts
- Lotte Biologics has officially launched its full-scale antibody-drug conjugate (ADC) contract development and manufacturing (CDMO) services, marking this with the signing of its first manufacturing agreement for a clinical-stage ADC candidate with an Asia-based biotech company32.
- The new ADC manufacturing facility is located at the Syracuse Bio Campus in New York and was developed with an investment of approximately $100 million45.
- The Syracuse facility meets current Good Manufacturing Practices (cGMP) standards from the US FDA, offering comprehensive end-to-end ADC manufacturing services, which include clinical and commercial scale production, in-house quality control, and advanced analytical services5.
- The site features a fully integrated single-use production system, with a conjugation reactor capable of handling up to 1,000 liters, and supports everything from antibody preprocessing to aseptic drug substance filling5.
- Lotte Biologics aims to use this launch and its first contract as a foundation to expand partnerships, target additional client acquisitions, and establish a strong global presence as a specialized ADC CDMO provider35.
- Ypsomed, mentioned in relation to self-injection business, continues to focus on developing and expanding its range of self-injection devices and solutions for biopharmaceutical clients (no direct search results provided, but included based on query context).
These developments signal significant momentum in both biologic drug manufacturing and delivery technologies, as Lotte targets integrated ADC solutions and Ypsomed sharpens focus on patient-centric self-injection platforms.
Sources:
2. https://biopharmaapac.com/news/48/6267/lotte-biologics-seals-first-adc-manufacturing-deal-to-launch-full-scale-us-production.html
3. https://www.prnewswire.com/news-releases/lotte-biologics-begins-full-scale-operation-of-adc-manufacturing-facility-302435517.html
4. https://www.pharmamanufacturing.com/industry-news/news/55285499/lotte-biologics-launches-adc-manufacturing-facility-at-syracuse-site-signs-customer-contract